Login
Search
Search
0 Dates
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Triple antithrombotic therapy in acute coronary syndrome in patients with moderate-high ischemic risk: How to define the duration of treatment taking into account the outcome?
Session:
Sessão de Posters 36 - Antiagregação plaquetar
Speaker:
Joana Massa Pereira
Congress:
CPC 2024
Topic:
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
Theme:
13. Acute Coronary Syndromes
Subtheme:
13.4 Acute Coronary Syndromes – Treatment
Session Type:
Cartazes
FP Number:
---
Authors:
Joana Massa Pereira; Sofia Andraz; Lucas Hamann; Hugo Alex Costa; Miguel Espírito Santo; Daniela Carvalho; Pedro Azevedo; Raquel Fernandes; Dina Bento; João Sousa Bispo; Hugo Vinhas; Jorge Mimoso
Abstract
<p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Introduction:</strong> Atrial fibrillation (AF) and flutter (AFL) increase the risk of thromboembolic events and may be indicated to initiate anticoagulation. In these patients, in case of an acute coronary syndrome (ACS), anticoagulation must be maintained during percutaneous coronary intervention (PCI) and continued thereafter. Differing in terms of duration, we can use a default triple antithrombotic therapy (TAT) or an extended therapy strategy.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Objective:</strong> Understand if patients with AF and/or AFL admitted due to an ACS and who underwent PCI had differences in terms of outcome<em>,</em> taking into account the duration of TAT (1 week - Default Strategy or 1-3 months – Extended Strategy). Additionally, the aim was to characterize the sample in terms of demographic characteristics, cardiovascular risk factors (CVRF), ischemic and hemorrhagic risk, as well as the type of therapy used.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Methods:</strong> Retrospective study included 65 patients with AF and/or AFL admitted due to an ACS and who underwent PCI between January 2020 and December 2021. The outcome studied was hospitalization due to cardiovascular (CV) cause, or unplanned PCI, or occurrence of a hemorrhagic event or CV death. Categorical variables are expressed as absolute value and frequency, while continuous variables as mean and standard deviation. Statistical evaluation was carried out using the Chi-Square Test or Fisher's Exact Test. p value <0.05 indicates statistical significance.</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Results:</strong> From 65 patients with AF and/or AFL, 49 received TAT (26.2% until 1 week and 49.2% between 1 to 3 months). They had an average age of 74.5±9.6 years, with 61.2% being male. In terms of CVRF 49.0% had <em>Diabetes Mellitus</em>, 87.8% dyslipidemia, 93.9% high blood pressure and 14.3% were smokers. The most common coronary event was acute myocardial infarction without ST segment elevation (61.2%). The majority had a moderate-high ischemic risk, with no differences between the TAT group treated until 1 week <em>versus</em> TAT group treated during 1-3 months (p=0.650). Differences were observed between groups when assessed bleeding risk using ARC-HBR evaluator with a greater number of individuals under TAT for 1-3 months than expected, when the hemorrhagic risk was low (p=0.043). There was no association between the composite outcome<em> </em>and the duration of TAT (p=0.231).</span></span></p> <p style="text-align:justify"><span style="font-size:11pt"><span style="font-family:Calibri,sans-serif"><strong>Conclusions:</strong> In patients with ACS and AF and/or AFL, the choice of TAT strategy should be guided by hemorrhagic risk, since it does not seem to lead to an increase in CV, ischemic or hemorrhagic events, when ischemic risk is moderate-high. </span></span></p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site